Posted by Michael Wonder on 01 Oct 2019
Fees for redeeming priority review vouchers fall to all-time low in FY2020
30 September 2019 - The US FDA on Friday announced the fees for using a priority review voucher to speed the review of a new drug, biologic or medical countermeasure for vouchers redeemed in FY2020.
The agency's three priority review voucher (PRV) programs are meant to incentivise drug development in underserved areas, such as tropical diseases, rare paediatric diseases and medical countermeasures used in public emergencies.
By using a PRV, a sponsor can receive a six month priority review for a new drug application or biologics license application that otherwise would not qualify for one.
